Solara Active Pharma Sciences reports consolidated Q2 FY25 net profit at Rs. 8.01 Cr
Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024
Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
Giri is currently the President (India Business & Emerging Markets) of Amneal Pharmaceuticals
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
Declan brings over 25 years of expertise in the pharmaceutical and biotech sectors
The GMP certificate will allow the manufacturing site in Hervás, Cáceres to manufacture active ingredients for the pharmaceutical industry that is based on medicinal plants
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
CSPC will receive an upfront payment of $100 million from AstraZeneca
Subscribe To Our Newsletter & Stay Updated